NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it will now provide its PlasmaSelect 64 liquid biopsy test to advanced cancer patients receiving treatment at US Department of Veterans Affairs facilities.

The agreement makes PGDx the first to provide plasma-based genomic profiling to VA cancer patients, expanding on an existing contract under which patients also have access to the company's tissue-based CancerSelect 125 assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.